Related references
Note: Only part of the references are listed.The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
CTCF: making the right connections
Rodolfo Ghirlando et al.
GENES & DEVELOPMENT (2016)
Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial
Srdan Verstovsek et al.
HAEMATOLOGICA (2016)
Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial
Srdan Verstovsek et al.
HAEMATOLOGICA (2016)
Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis
Rami S. Komrokji et al.
BLOOD (2015)
Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera
Heinz Gisslinger et al.
BLOOD (2015)
CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms
Sara C. Meyer et al.
CANCER CELL (2015)
Emerging drugs for the treatment of myelofibrosis
Holly L. Geyer et al.
EXPERT OPINION ON EMERGING DRUGS (2015)
Romidepsin for the treatment of non-Hodgkin's lymphoma
Victor Y. Yazbeck et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2015)
Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study
Owen A. O'Connor et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group
N. M. Kroeger et al.
LEUKEMIA (2015)
A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis
Ayalew Tefferi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
Alessandro M. Vannucchi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia
T. Barbui et al.
BLOOD CANCER JOURNAL (2015)
Ruxolitinib and DNA methyltransferase-inhibitors: a foray into combination regimens in myelofibrosis
Naval Daver et al.
LEUKEMIA & LYMPHOMA (2015)
The Bone Marrow-Mediated Protection of Myeloproliferative Neoplastic Cells to Vorinostat and Ruxolitinib Relies on the Activation of JNK and PI3K Signalling Pathways
Bruno A. Cardoso et al.
PLOS ONE (2015)
JAK2V617F homozygosity drives a phenotypic switch in myeloproliferative neoplasms, but is insufficient to sustain disease
Juan Li et al.
BLOOD (2014)
Therapy for myeloproliferative neoplasms: when, which agent, and how?
Holly L. Geyer et al.
BLOOD (2014)
Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients
Holly L. Geyer et al.
BLOOD (2014)
Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis
Raajit Rampal et al.
BLOOD (2014)
Molecular Pathways: Molecular Basis for Sensitivity and Resistance to JAK Kinase Inhibitors
Sara C. Meyer et al.
CLINICAL CANCER RESEARCH (2014)
Prolonged Administration of Azacitidine With or Without Entinostat for Myelodysplastic Syndrome and Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905
Thomas Prebet et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Novel myelofibrosis treatment strategies: potential partners for combination therapies
B. L. Stein et al.
LEUKEMIA (2014)
Are we altering the natural history of primary myelofibrosis?
Michael R. Savona
LEUKEMIA RESEARCH (2014)
Histone deacetylase inhibitor (HDACI) mechanisms of action: Emerging insights
Prithviraj Bose et al.
PHARMACOLOGY & THERAPEUTICS (2014)
A comprehensive review and analysis of the effect of ruxolitinib therapy on the survival of patients with myelofibrosis
John Mascarenhas et al.
BLOOD (2013)
Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis
Daniel J. DeAngelo et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia
Christen L. Andersen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF)
John Mascarenhas et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy
Guido Finazzi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Pure curcumin increases the expression of SOCS1 and SOCS3 in myeloproliferative neoplasms through suppressing class histone deacetylases
Chi-qi Chen et al.
CARCINOGENESIS (2013)
JAK1/2 and Pan-Deacetylase Inhibitor Combination Therapy Yields Improved Efficacy in Preclinical Mouse Models of JAK2V617F-Driven Disease
Emeline Evrot et al.
CLINICAL CANCER RESEARCH (2013)
Histone deacetylases inhibitor sodium butyrate inhibits JAK2/STAT signaling through upregulation of SOCS1 and SOCS3 mediated by HDAC8 inhibition in myeloproliferative neoplasms
Shen-meng Gao et al.
EXPERIMENTAL HEMATOLOGY (2013)
Givinostat and hydroxyurea synergize in vitro to induce apoptosis of cells from JAK2V617F myeloproliferative neoplasm patients
Ariel Amaru Calzada et al.
EXPERIMENTAL HEMATOLOGY (2013)
Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study
A. Tefferi et al.
LEUKEMIA (2013)
Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
A. Pardanani et al.
LEUKEMIA (2013)
Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
J. Nangalia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Oncogenic CSF3R Mutations in Chronic Neutrophilic Leukemia and Atypical CML
Julia E. Maxson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
Thorsten Klampfl et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Cardiovascular Events and Intensity of Treatment in Polycythemia Vera
Roberto Marchioli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
The cell cycle regulator CDC25A is a target for JAK2V617F oncogene
Emilie-Fleur Gautier et al.
BLOOD (2012)
Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)
Tiziano Barbui et al.
BLOOD (2012)
Efficacy of vorinostat in a murine model of polycythemia vera
Hajime Akada et al.
BLOOD (2012)
A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment
Francesco Passamonti et al.
BLOOD (2012)
The HDAC inhibitor Givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2V617F myeloproliferative neoplasm cells
Ariel Amaru Calzada et al.
EXPERIMENTAL HEMATOLOGY (2012)
Panobinostat (LBH589)-induced acetylation of tubulin impairs megakaryocyte maturation and platelet formation
Camelia Iancu-Rubin et al.
EXPERIMENTAL HEMATOLOGY (2012)
Improving Survival Trends in Primary Myelofibrosis: An International Study
Francisco Cervantes et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy
Bertrand Coiffier et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
A novel murine model of myeloproliferative disorders generated by overexpression of the transcription factor NF-E2
Kai B. Kaufmann et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
Increased gene expression of histone deacetylases in patients with Philadelphia-negative chronic myeloproliferative neoplasms
Vibe Skov et al.
LEUKEMIA & LYMPHOMA (2012)
Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis
Alfonso Quintas-Cardama et al.
LEUKEMIA RESEARCH (2012)
Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy
Priya Koppikar et al.
NATURE (2012)
Modulation of Activation-Loop Phosphorylation by JAK Inhibitors Is Binding Mode Dependent
Rita Andraos et al.
CANCER DISCOVERY (2012)
Increased basal intracellular signaling patterns do not correlate with JAK2 genotype in human myeloproliferative neoplasms
Shubha Anand et al.
BLOOD (2011)
New mutations and pathogenesis of myeloproliferative neoplasms
William Vainchenker et al.
BLOOD (2011)
Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia
Mark J. Bishton et al.
BLOOD (2011)
JAK2V617F-Mediated Phosphorylation of PRMT5 Downregulates Its Methyltransferase Activity and Promotes Myeloproliferation
Fan Liu et al.
CANCER CELL (2011)
Akt activation through the phosphorylation of erythropoietin receptor at tyrosine 479 is required for myeloproliferative disorder-associated JAK2 V617F mutant-induced cellular transformation
Jun Kamishimoto et al.
CELLULAR SIGNALLING (2011)
Heat Shock Protein 90 Inhibitor Is Synergistic with JAK2 Inhibitor and Overcomes Resistance to JAK2-TKI in Human Myeloproliferative Neoplasm Cells
Warren Fiskus et al.
CLINICAL CANCER RESEARCH (2011)
Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet
Tiziano Barbui et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia
A. Quintas-Cardama et al.
LEUKEMIA (2011)
Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies
John Mascarenhas et al.
CLINICAL EPIGENETICS (2011)
A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process
Giovanni Barosi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: defining molecular mechanisms of resistance
Wenlin Shao et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans
Sachie Marubayashi et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joining
Kyle M. Miller et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2010)
Downregulation of Homologous Recombination DNA Repair Genes by HDAC Inhibition in Prostate Cancer Is Mediated through the E2F1 Transcription Factor
Sushant K. Kachhap et al.
PLOS ONE (2010)
Histone Deacetylase Inhibitors Downregulate Checkpoint Kinase 1 Expression to Induce Cell Death in Non-Small Cell Lung Cancer Cells
William Brazelle et al.
PLOS ONE (2010)
Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair
J-H. Lee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
Francisco Cervantes et al.
BLOOD (2009)
Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference
Giovanni Barosi et al.
BLOOD (2009)
Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells
Yongchao Wang et al.
BLOOD (2009)
Histone Deacetylase Inhibitors in Cancer Therapy
Andrew A. Lane et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera
Alfonso Quintas-Cardama et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
JAK2 phosphorylates histone H3Y41 and excludes HP1α from chromatin
Mark A. Dawson et al.
NATURE (2009)
SOCS-mediated downregulation of mutant Jak2 ( V617F, T875N and K539L) counteracts cytokine-independent signaling
S. Haan et al.
ONCOGENE (2009)
Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera
Jean-Jacques Kiladjian et al.
BLOOD (2008)
Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control
Srividya Bhaskara et al.
MOLECULAR CELL (2008)
Enhanced histone deacetylase enzyme activity in primary myelofibrosis
Jen Chin Wang et al.
LEUKEMIA & LYMPHOMA (2008)
The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men
Xiang-Jiao Yang et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2008)
Histone deacetylase 3 localizes to the mitotic spindle and is required for kinetochore-microtubule attachment
Sumiyasu Ishii et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Hypermethylation of CXCR4 promoter in CD34+ cells from patients with primary myelofibrosis
Costanza Bogani et al.
STEM CELLS (2008)
The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2V617F
V. Guerini et al.
LEUKEMIA (2008)
Histone deacetylase inhibitors induce mitotic slippage
F. E. Stevens et al.
ONCOGENE (2008)
HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination
Shanthi Adimoolam et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Genome-wide maps of chromatin state in pluripotent and lineage-committed cells
Tarjei S. Mikkelsen et al.
NATURE (2007)
Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma
Elise A. Olsen et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Effects of chromatin-modifying agents on CD34+ cells from patients with idiopathic myelofibrosis
Jun Shi et al.
CANCER RESEARCH (2007)
Histone deacetylase inhibitors induce premature sister chromatid separation and override the mitotic spindle assembly checkpoint
Laura Magnaghi-Jaulin et al.
CANCER RESEARCH (2007)
The expression of CXCR4 is down-regulated on the CD34+cells of patients with myelofibrosis with myeloid metaplasia
Vittorio Rosti et al.
BLOOD CELLS MOLECULES AND DISEASES (2007)
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis
Linda M. Scott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
MPL515 mutations in myeloproliferative and other myeloid disorders:: a study of 1182 patients
Animesh D. Pardanani et al.
BLOOD (2006)
International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT)
Ayalew Tefferi et al.
BLOOD (2006)
Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders
Robert Kralovics et al.
BLOOD (2006)
MPLW515L is anovel somatic activating mutation in myelofibrosis with myeloid metaplasia
Yana Pikman et al.
PLOS MEDICINE (2006)
Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET)
G Barosi et al.
BLOOD (2005)
Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90 - A novel basis for antileukemia activity of histone deacetylase inhibitors
P Bali et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies
KN Bhalla
JOURNAL OF CLINICAL ONCOLOGY (2005)
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
C James et al.
NATURE (2005)
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
RL Levine et al.
CANCER CELL (2005)
Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors
JS Ungerstedt et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia
F Passamonti et al.
AMERICAN JOURNAL OF MEDICINE (2004)
Deacetylase activity is required for recruitment of the basal transcription machinery and transactivation by STAT5
A Rascle et al.
MOLECULAR AND CELLULAR BIOLOGY (2003)
Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation
VM Richon et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Share Paper
